Project 2

$572,796P01FY2014CANIH

Cold Spring Harbor Laboratory, Cold Spg Hbr NY

Investigators

Linked publications & trials

Paper 39192144 Paper 39058094 Paper 38886586 Paper 38716830 Paper 38562717 Paper 38409339 Paper 38402610 Paper 38401489 Paper 38309274 Paper 38262672 Paper 38110836 Paper 37961243 Paper 37922916 Paper 37639593 Paper 37261974 Paper 37098965 Paper 37066201 Paper 37043556 Paper 37037615 Paper 36949200 Paper 36928165 Paper 36912618 Paper 36876940 Paper 36697233 Paper 36658219 Paper 36640769 Paper 36596869 Paper 36544023 Paper 36475926 Paper 36344707 Paper 36302222 Paper 36264143 Paper 35978189 Paper 35835117 Paper 35576971 Paper 35180770 Paper 35165384 Paper 35068483 Paper 35021089 Paper 34921016 Paper 34702734 Paper 34556174 Paper 34531253 Paper 34509979 Paper 34377737 Paper 34016956 Paper 34002693 Paper 33893150 Paper 33860086 Paper 33761311 Paper 33536616 Paper 33527899 Paper 33522487 Paper 33353933 Paper 33056978 Paper 32633781 Paper 32606137 Paper 32503170 Paper 32416589 Paper 32385160 Paper 32329713 Paper 32234521 Paper 32188706 Paper 32051529 Paper 32001512 Paper 31951519 Paper 31802121 Paper 31775037 Paper 31697837 Paper 31554806 Paper 31551264 Paper 31534224 Paper 31454099 Paper 31406271 Paper 31398338 Paper 31222014 Paper 31135034 Paper 30965276 Paper 30874469 Paper 30865883 Paper 30763770 Paper 30620551 Paper 30561826 Paper 30503706 Paper 30431433 Paper 30428345 Paper 30218786 Paper 30107180 Paper 30100187 Paper 30039733 Paper 30014851 Paper 29983885 Paper 29958801 Paper 29945888 Paper 29871936 Paper 29853643 Paper 29777171 Paper 29526696 Paper 29502955 Paper 29449148

Abstract

The central goal of Project 2 is to understand the role of alternative splicing in cancer. Cancer cells display extensive qualitative and quantitative dysregulation of splicing, and a subset of the isoforms that are inappropriately expressed can contribute to tumorigenesis. The mechanisms and pathways through which the splicing-factor oncoprotein SRSF1 and related members of the SR protein family transform cells will be investigated. Organotypic culture, as well as orthotopic and transgenic mouse models will be used to study transformation promoted by these splicing factors and their cooperation with other oncogenes in different cancer contexts. How these factors themselves are regulated in normal cells and upregulated in cancer will be addressed. High-throughput methods will be employed to systematically identify the splicing targets of SR proteins in human cells, and selected targets involved in tumorigenesis will be analyzed in detail. Splicing factors that contribute to the distinctive glycolytic metabolism of cancer cells will be identified and characterized, and alternative splicing of pyruvate kinase pre-mRNA will be investigated as a potential therapeutic target by specifically manipulating this process in tumors.

View original record on NIH RePORTER →